SOURCE: Biophan Technologies, Inc.

December 18, 2007 07:11 ET

Biophan Announces Appointment of James Goldberg as Interim President for Myotech

PITTSFORD, NY--(Marketwire - December 18, 2007) - Biophan Technologies, Inc. (OTCBB: BIPH), a developer of next-generation biomedical technology, today announced the appointment of James Goldberg as interim President of Myotech, LLC, effective immediately. Myotech is a majority-owned subsidiary of Biophan Technologies, Inc.

Mr. Goldberg, an entrepreneur and inventor, has founded or co-founded multiple companies, including Therics, Inc., a tissue engineering and drug delivery company, begun at MIT and based on Johnson & Johnson funded research. He also served as Executive Medical Director of Lawrence Livermore National Labs (LLNL), and as CEO of Endovasix, a medical device company based upon technology developed at LLNL.

In 1970, Mr. Goldberg founded Theta Resources, and for eighteen years served as Director of this multi-disciplinary, incubator-style, product design, technology development and engineering company.

Most recently, from 2004 to 2006, he has been an advisor to the United States Senate Finance Committee on Health Care and Medicare. Previously Mr. Goldberg was Executive Vice President of ANGLE Technology, PLC, consulting on the commercialization of intellectual property working both with the private and public sectors.

In 2000 he founded SmartAnalyst, which provides corporate research services employing a highly skilled Indian research team empowered by leading edge research software.

Mr. Goldberg's academic credentials in technology, IT, strategy and project management have been earned at Michigan State, Stanford University, New York University, The University of Mainz, The Sorbonne and the University of Madrid. Mr. Goldberg is a sought-after and frequent lecturer and consultant on health care technologies, patient care and bio medical technology innovation.

John Lanzafame, Biophan Chief Executive Officer, stated, "As the Myotech Circulatory Support System (CSS) moves toward clinical trials and ultimately market entry, Jim Goldberg's vast experience in running early- and mid-stage healthcare companies will be an invaluable asset."

Mr. Goldberg commented, "This is a very pivotal period in the Myotech's development, and I am honored to have an opportunity to contribute to its growth and development as the company moves closer to commercialization."

The Myotech Circulatory Support System (CSS) consists of an external drive unit and flexible polymer cup that slips over the heart and provides the energy that enables the heart to restore normal blood flow. It can be installed in approximately three minutes with a small incision to provide immediate, life-saving support in emergency situations. Since it has no contact with circulating blood, the Myotech CSS also promises to reduce the risk of patient complications, such as clotting and stroke, bleeding, and infection.

About Biophan Technologies, Inc.

Biophan is dedicated to providing technologies that offer innovative and competitive advantages to the medical device industry. The Company is helping to commercialize the Myotech Circulatory Support System, which has significant potential to improve the treatment of acute heart failure. Biophan Technologies, Inc. holds a 68% interest in Myotech with rights to acquire additional equity, and is leading Myotech's business development efforts. Biophan is traded on the OTC market under the symbol BIPH, and is also listed on the Frankfurt Stock Exchange under the symbol BTN. For more information on Biophan, please visit our website at

Cautionary Statement Regarding Forward-Looking Statements

Certain statements included in this press release may constitute forward-looking statements within the meaning of applicable securities laws. These statements reflect what Biophan anticipates, expect, or believe may happen in the future. Biophan's actual results could differ materially from the outcome or circumstance expressed or implied by such forward-looking statements as a result of a variety of factors including, but not limited to: Biophan's ability to develop its technologies; the approval of Biophan's patent applications; the successful implementation of Biophan's research and development programs; the ability of Biophan to demonstrate the effectiveness of its technology; the acceptance by the market of Biophan's technology and products incorporating such technology; the ability of Biophan to effectively negotiate and enter into contracts with medical device manufacturers for the licensing of Biophan's technology; competition; the ability of Biophan to raise capital to fund its operating and research and development activities until it generates revenues sufficient to do so; and the timing of projects and trends in future operating performance, as well as other factors expressed from time to time in Biophan's periodic filings with the Securities and Exchange Commission (the "SEC"). As a result, this press release should be read in conjunction with Biophan's periodic filings with the SEC, which are incorporated herein by reference. The forward-looking statements contained herein are made only as of the date of this press release, and Biophan undertakes no obligation to publicly update such forward-looking statements to reflect subsequent events or circumstances.

Contact Information

  • Contact:
    Carolyn Hotchkiss
    Communications Manager
    Biophan Technologies, Inc.
    (585) 267-4813
    Email Contact